List of withdrawn drugs

!Drug name

!Withdrawn

!Country

!class="unsortable"|Remarks

|2005

|Canada

|Withdrawn over reports of increased risk of stroke, reinstated after increased risk not found.{{cite web|url=http://www.hc-sc.gc.ca/english/protection/warnings/2005/2005_01.html|title=Health Canada – Home Page|first=Government of Canada, Health Canada, Public Affairs, Consultation and Communications|last=Branch|access-date=28 November 2016|url-status=dead|archive-url=https://web.archive.org/web/20050628074032/http://www.hc-sc.gc.ca/english/protection/warnings/2005/2005_01.html|archive-date=28 June 2005}}

|2006

|Worldwide

|Serious hepatotoxicity leading to liver transplant or death.

|1979

|UK

|Vasculitis{{cite journal|last=Fung|first=M.|author2=Thornton, A. |author3=Mybeck, K. |author4=Wu, J. H.-h. |author5=Hornbuckle, K. |author6= Muniz, E. |title=Evaluation of the Characteristics of Safety Withdrawal of Prescription Drugs from Worldwide Pharmaceutical Markets-1960 to 1999|journal=Therapeutic Innovation & Regulatory Science|date=1 January 2001|volume=35|issue=1|pages=293–317|doi=10.1177/009286150103500134|s2cid=73036562}}

|1995

|Worldwide

|Not approved in the US, withdrawn in France in 1994{{cite web|url=http://whqlibdoc.who.int/druginfo/DRUG_INFO_8_2_1994.pdf|title=WHO Drug Information Vol. 8, No. 2, 1994, page 64|access-date=28 November 2016|url-status=dead|archive-url=https://web.archive.org/web/20120303224305/http://whqlibdoc.who.int/druginfo/DRUG_INFO_8_2_1994.pdf|archive-date=3 March 2012}} and the rest of the market in 1995 because of rare but serious hepatotoxicity.{{cite journal | last1 = Berson | first1 = A |display-authors=etal | year = 2001 | title = Toxicity of alpidem, a peripheral benzodiazepine receptor ligand, but not zolpidem, in rat hepatocytes: role of mitochondrial permeability transition and metabolic activation | url = http://jpet.aspetjournals.org/content/299/2/793.full.pdf | journal = J Pharmacol Exp Ther | volume = 299 | issue = 2| pages = 793–800 | doi = 10.1016/S0022-3565(24)29292-2 | pmid = 11602696 }}

|2000

|US

|Serious gastrointestinal adverse events; ischemic colitis; severe constipation. Reintroduced 2002 with restricted indication and new controls.{{Cite news|last=Grady|first=Denise|date=2002-06-08|title=U.S. Lets Drug Tied to Deaths Back on Market|language=en-US|work=The New York Times|url=https://www.nytimes.com/2002/06/08/us/us-lets-drug-tied-to-deaths-back-on-market.html|access-date=2021-07-20|issn=0362-4331}}

|1984

|France, Germany, UK

|Anaphylaxis, possibly due to carrier oil (Cremophor EL).

|1999

|France, US

|Hepatotoxicity, dermatological side effects, and abuse potential.{{cite web|last=DrugBank|title=Amineptine|url=http://www.drugbank.ca/drugs/DB04836|access-date=24 September 2013|url-status=live|archive-url=https://web.archive.org/web/20130927055156/http://www.drugbank.ca/drugs/DB04836|archive-date=27 September 2013}}

|1999

|France, Thailand

|Risk of agranulocytosis and severe acne.

|1980

|Norway

|Risk of barbiturate toxicity.

|1970

|France

|Dermatologic and ophthalmic toxicity.

|1969

|Germany

|Animal carcinogenicity.

|1984

|France

|Unspecific experimental toxicity.

|2008

|US

|Increased risk of death.

|2001

|US

|Withdrawn at request of NDA originator, "not for reason of safety or efficacy."{{Cite web|date=2002-05-23|title=Determination That Ardeparin Sodium Injection Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness|url=https://www.federalregister.gov/documents/2002/05/23/02-12874/determination-that-ardeparin-sodium-injection-was-not-withdrawn-from-sale-for-reasons-of-safety-or|access-date=2021-07-20|website=Federal Register}}{{cite web|url=https://www.fda.gov/ohrms/dockets/98fr/052302b.htm|title=FDA Response to Citizen Request re Ardeparin|website=fda.gov|access-date=28 April 2018|url-status=live|archive-url=https://web.archive.org/web/20170118093137/https://www.fda.gov/ohrms/dockets/98fr/052302b.htm|archive-date=18 January 2017}}

|1999

|US, Malaysia, Multiple nonspecified markets

|Fatal arrhythmia

|1976

|US

|Thromboembolism.

|1993

|Spain

|Hepatotoxicity.

|1982

|Germany, Spain, UK, US

|Liver and kidney failure; gastrointestinal bleeding; ulcers.{{cite journal|last=Qureshi|first=ZP|author2=Seoane-Vazquez, E |author3=Rodriguez-Monguio, R |author4=Stevenson, KB |author5= Szeinbach, SL |title=Market withdrawal of new molecular entities approved in the United States from 1980 to 2009.|journal=Pharmacoepidemiology and Drug Safety|date=July 2011|volume=20|issue=7|pages=772–7|pmid=21574210|doi=10.1002/pds.2155|s2cid=23821961}}

|1992

|Germany

|Hepatitis.

|1964

|France, UK

|Jaundice.

|1986

|Germany

|Renal toxicity, animal carcinogenicity.

|2004

|Netherlands

|Risk of fatal overdose{{cite web|last=DrugBank|title=Bezitramide|url=http://www.drugbank.ca/drugs/DB01459|access-date=24 September 2013|url-status=dead|archive-url=https://web.archive.org/web/20130927055256/http://www.drugbank.ca/drugs/DB01459|archive-date=27 September 2013}}

|1967

|US

|Dermatologic toxicity.

|1989

|UK

|Animal carcinogenicity.

|1998

|US

|Severe hepatitis and liver failure (requiring transplantation).

|1986

|Germany

|Kidney damage

|1978

|Germany

|Metabolic toxicity.

|1963

|Canada, UK, US

|Nephropathy.{{cite web|last=DrugBank|title=Bunamiodyl|url=http://www.drugbank.ca/drugs/DB04814|access-date=24 September 2013|url-status=live|archive-url=https://web.archive.org/web/20130927055201/http://www.drugbank.ca/drugs/DB04814|archive-date=27 September 2013}}

|1964

|US

|Dermatologic toxicity; psychiatric reactions.

|1986

|Germany

|Animal Carcinogenicity.

|2001

|US

|Risk of rhabdomyolysis

|1970

|UK, US

|Animal Carcinogenicity.

|1996

|European Union, US, South Africa, Japan

|Hepatotoxicity and Stevens–Johnson Syndrome

|1969

|Germany

|Cardiovascular Toxicity.

|1985

|France, Germany, Spain, Sweden

|Hemolytic Anemia.

|1988

|Spain

|Agranulocytosis.WHO. [http://apps.who.int/medicinedocs/en/d/Js16780e/ Consolidated List of Products – Whose Consumption and/or Sale Have Been Banned, Withdrawn, Severely Restricted or Not Approved by Governments, Twelfth Issue – Pharmaceuticals] {{webarchive|url=http://archive.wikiwix.com/cache/20141109034942/http://apps.who.int/medicinedocs/en/d/Js16780e/ |date=2014-11-09 }}. United Nations – New York, 2005Department of Economic and Social Affairs of the United Nations Secretariat [https://www.un.org/esa/coordination/CL12.pdf Consolidated List of Products Whose Consumption and/or Sale Have Been Banned, Withdrawn, Severely Restricted or not Approved by Governments Twelfth Issue: Pharmaceuticals] {{webarchive|url=https://web.archive.org/web/20121023143706/http://www.un.org/esa/coordination/CL12.pdf |date=2012-10-23 }} United Nations – New York, 2005

|2000

|US

|Risk of fatal cardiac arrhythmias

|1973

|France, Germany, UK, US

|Neurotoxicity.

|2007

|Germany

|Ventricular arrhythmia, QT-prolongation.{{cite news|last=Schubert-Zsilavecz|first=Manfred|title=Arzneimittelrücknahmen Rückrufe im Rückblick|url=http://www.pharmazeutische-zeitung.de/index.php?id=38778|access-date=25 September 2013|newspaper=Pharmazeutische Zeitung (German)|year=2011|url-status=live|archive-url=https://web.archive.org/web/20130927201918/http://www.pharmazeutische-zeitung.de/index.php?id=38778|archive-date=27 September 2013}}

|1969

|Germany

|Cardiovascular toxicity.

|1982

|UK

|Hepatotoxicity.

|1987

|France

|Hepatotoxicity.

|2004

|UK

|Risk of overdose

|1980

|Norway

|Risk of overdose

|1987

|France

|Hepatotoxicity.

|1963

|Canada, UK, US

|Mutagenic.{{cite web|last=DrugBank|title=Dantron|url=http://www.drugbank.ca/drugs/DB04816|access-date=24 September 2013|url-status=live|archive-url=https://web.archive.org/web/20130927055048/http://www.drugbank.ca/drugs/DB04816|archive-date=27 September 2013}} withdrawn from general use in UK but permitted in terminal patients

|1997

|European Union, UK, US

|Cardiotoxic

|2010

|Worldwide

|Increased risk of heart attacks and stroke.{{cite web|url=https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm234350.htm|title=Press Announcements – Xanodyne agrees to withdraw propoxyphene from the U.S. market|website=Food and Drug Administration|access-date=28 November 2016|url-status=live|archive-url=https://web.archive.org/web/20161113155019/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm234350.htm|archive-date=13 November 2016}}

|1971

|Australia

|Hepatotoxicity.

|1970s

|US

|Carcinogen

|1986

|Germany

|Multi-Organ toxicities.

|1970

|US

|Neuropsychiatric reaction.

|1990

|UK

|Hepatotoxicity.

|1972

|France, US

|Neuropsychiatric reaction.

|1983

|US

|Voluntarily withdrawn from market by Lily.Col John Lammie et al. [http://home.fhpr.osd.mil/Libraries/pdf/Report_of_the_DoD_DMAA_Safety_Review_Panel_2013.sflb.ashx Report of the Department Of Defense: 1,3 Dimethylamylamine (Dmaa) Safety Review Panel] {{webarchive|url=https://web.archive.org/web/20140119112259/http://home.fhpr.osd.mil/Libraries/pdf/Report_of_the_DoD_DMAA_Safety_Review_Panel_2013.sflb.ashx |date=2014-01-19 }} June 3, 2013{{rp|12}} Reintroduced as a dietary supplement in 2006;{{rp|13}} in 2013 the FDA started work to ban it due to cardiovascular problems{{cite web|last=FDA|title=Stimulant Potentially Dangerous to Health, FDA Warns|website=Food and Drug Administration|url=https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm347270.htm|access-date=26 January 2014|url-status=live|archive-url=https://web.archive.org/web/20140201191226/https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm347270.htm|archive-date=1 February 2014}}

|1990

|UK

|Uterine hypotonus, fetal distress.

|1975

|UK, US, Others

|Agranulocytosis, anaphylactic reactions.

|1964

|France, US

|Cardiovascular and metabolic reaction.

|2004

|Germany

|Drug interactions, prolonged QT.

|2011

|Worldwide

|Lack of efficacy as shown by PROWESS-SHOCK study[http://www.nejm.org/doi/full/10.1056/NEJMoa1202290 Drotrecogin Alfa (Activated) in Adults with Septic Shock ] {{webarchive|url=https://web.archive.org/web/20150929001734/http://www.nejm.org/doi/full/10.1056/NEJMoa1202290 |date=2015-09-29 }}, N Engl J Med 2012; 366:2055–2064, May 31, 2012, {{doi|10.1056/NEJMoa1202290}}{{cite web |title=Xigris (drotrecogin alfa (activated)) to be withdrawn due to lack of efficacy |work=Press release |publisher=European Medicines Agency |location=London, UK |url=http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fnews_and_events%2Fnews%2F2011%2F10%2Fnews_detail_001373.jsp&mid=WC0b01ac058004d5c1 |archive-url=https://web.archive.org/web/20111028112048/http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fnews_and_events%2Fnews%2F2011%2F10%2Fnews_detail_001373.jsp&mid=WC0b01ac058004d5c1 |archive-date=28 October 2011 |date=25 October 2011 |access-date=26 October 2011 |url-status=dead }}{{cite web|last=Armstrong|first=Drew|date=25 October 2011|title=Lilly Pulls Xigris Off Markets After Sepsis Drug Fails Study|url=http://www.businessweek.com/news/2011-10-25/lilly-pulls-xigris-off-markets-after-sepsis-drug-fails-study.html|url-status=dead|archive-url=https://web.archive.org/web/20111029155823/http://www.businessweek.com/news/2011-10-25/lilly-pulls-xigris-off-markets-after-sepsis-drug-fails-study.html|archive-date=2011-10-29|access-date=2011-10-25|website=Bloomberg Businessweek}}

|1998

|Spain

|Hepatotoxicity.

|2009

|Germany

|Withdrawn because of increased risk of progressive multifocal leukoencephalopathy

|1991

|UK, US

|Ventricular arrhythmias.

|1963

|Canada, UK, US

|Carcinogen.{{cite web|last=DrugBank|title=Ethyl carbamate|url=http://www.drugbank.ca/drugs/DB04827|access-date=24 September 2013|url-status=live|archive-url=https://web.archive.org/web/20130927055159/http://www.drugbank.ca/drugs/DB04827|archive-date=27 September 2013}}

|1989

|France

| Teratogen.

|1989

|France

|Hepatotoxicity.

|1997

|

|Cardiotoxicity

|1984

|UK

|Cutaneous reactions; animal carcinogenicity.

|1970

|UK, US

|Hepatotoxicity.

|1997

|European Union, UK, US, India, South Africa, others

|Cardiac valvular disease, pulmonary hypertension, cardiac fibrosis;{{cite web|last=DrugBank|title=Fenfluramine|url=http://www.drugbank.ca/drugs/DB00574|access-date=24 September 2013|url-status=live|archive-url=https://web.archive.org/web/20130927055055/http://www.drugbank.ca/drugs/DB00574|archive-date=27 September 2013}} re-approved in June 2020 for the treatment of seizures associated with Dravet syndrome, under FDA orphan drug rules.

|1990

|New Zealand

|Asthma mortality.

|1984

|Germany, UK

|Cutaneous reaction, multiorgan toxicity.

|1991

|France

|Hepatotoxicity.

|1993

|UK, US

|Increased mortality at higher doses; increased hospitalizations.

|1991

|France

|Abuse.

|2018

|European Union

|Liver toxicity.{{cite web|title=Withdrawal of pain medicine flupirtine endorsed|url=http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/03/news_detail_002930.jsp&mid=WC0b01ac058004d5c1|access-date=13 July 2018}}

|2006

|US

|Increased risk of dysglycemia.

|2010

|US

|No improvement in clinical benefit; risk for death. Returned to market in 2017.{{cite web|last=FDA|title= FDA approves Mylotarg for treatment of acute myeloid leukemia|website= Food and Drug Administration|url= https://www.fda.gov/news-events/press-announcements/fda-approves-mylotarg-treatment-acute-myeloid-leukemia |access-date=17 February 2020}}

|1984

|France, Germany

|Anaphylaxis.

|1999

|Withdrawn Germany, UK, US others

|Cardiac repolarization; QT interval prolongation.

|2005

|

|High risk of accidental overdose when extended release version (Palladone) administered with alcohol. Standard hydromorphone is sold in most of the world including the US

|1968

|UK

|Hepatotoxicity, jaundice.

|1985

|France

|Agranulocytosis.

|1983

|Germany, Spain, UK

|Animal carcinogenicity, gastrointestinal toxicity.

|2020

|Suspended in Europe

|Increased risk of skin cancers.{{cite web|last=European medicines Agency|title=EMA suspends Picato as a precaution while review of skin cancer risk continues|url=https://www.ema.europa.eu/en/documents/referral/picato-article-20-referral-ema-suspends-picato-precaution-while-review-skin-cancer-risk-continues_en.pdf}}{{Cite web|url=https://www.gov.uk/drug-safety-update/ingenol-mebutate-gel-picato-increased-incidence-of-skin-tumours-seen-in-some-clinical-studies|title = Ingenol mebutate gel (Picato▼): Increased incidence of skin tumours seen in some clinical studies}}

|1964

|US

|Metabolic reaction.

|1964

|Canada

|Interactions with food products containing tyrosine.{{cite web|last=DrugBank|title=Iproniazid|url=http://www.drugbank.ca/drugs/DB04818|access-date=24 September 2013|url-status=live|archive-url=https://web.archive.org/web/20130927055058/http://www.drugbank.ca/drugs/DB04818|archive-date=27 September 2013}}

|1984

|France

|Hepatotoxicity.

|1983

|France, Germany, Spain, others

|Stevens–Johnson syndrome.

|2002

|Germany

|Hepatotoxicity.

|1993

|France, Germany, others

|Hemorrhage, Kidney Failure.

|1989

|Germany, UK

|Eosinophilic myalgia syndrome. Still sold in the US

|1999

| US

|Still used as veterinary drug and as a human antihelminthic in many markets; listed on the WHO List of Essential Medicines. In humans, it was used to treat melanoma before it was withdrawn for agranulocytosis.{{cite journal |title=Agranulocytosis associated with cocaine use – four States, March 2008 – November 2009 |journal=Morb. Mortal. Wkly. Rep. |volume=58 |issue=49 |pages=1381–5 |date=December 2009 |pmid=20019655 |url=https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5849a3.htm |author1=Centers for Disease Control and Prevention (CDC) |url-status=live |archive-url=https://web.archive.org/web/20170625012342/https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5849a3.htm |archive-date=2017-06-25 }}{{cite journal |author1=Nancy Y Zhu |author2=Donald F. LeGatt |author3=A Robert Turner | title=Agranulocytosis After Consumption of Cocaine Adulterated With Levamisole | journal=Annals of Internal Medicine | volume=150 | issue=4 |date=February 2009 | pages=287–289 | pmid=19153405 | doi=10.7326/0003-4819-150-4-200902170-00102}}{{cite journal | url=http://www.mdconsult.com/das/article/body/154945316-2/jorg=journal&source=&sp=21877276&sid=0/N/691072/1.html?issn=01960644 | title=Levamisole Found in Patients Using Cocaine | journal=Annals of Emergency Medicine | volume=53 | issue=4 | date=April 2009 | first=Erik | last=Kinzie | access-date=2009-08-18 | doi=10.1016/j.annemergmed.2008.10.017 | pages=546–7 | pmid=19303517 | url-status=live | archive-url=https://web.archive.org/web/20151224104135/http://www.mdconsult.com/das/article/body/154945316-2/jorg%3Djournal%26source%3D%26sp%3D21877276%26sid%3D0/N/691072/1.html?issn=01960644 | archive-date=2015-12-24 | doi-access=free }}

|2003

|US

|Cardiac arrhythmias and cardiac arrest.

|2020

|US

|Increased risk of cancer.{{cite journal|last=FDA|title= FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market|journal= FDA|date= 13 February 2020|url= https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-withdrawal-weight-loss-drug-belviq-belviq-xr-lorcaserin-market |access-date=17 February 2020}}

|2007–2008

|Worldwide

|Liver damage

|1950s–1960s

|

|Marketed as a psychiatric drug; withdrawn after it became widely used recreationally. Now illegal in most of the world.

|1975

|UK

|Hepatotoxicity, drug intereaction.

|1982

|France, Germany, UK, US, others

|Off-label abuse.

|1979

|Germany, UK, US

|Animal carcinogenicity.

|1984

|South Africa (1971), India (1984), United Nations (1971–1988)

|Withdrawn because of risk of addiction and overdose{{cite web|last=Central Drugs Standard Control Organization |title=Drugs Banned In India |url=http://cdsco.nic.in/html/drugsbanned.html |publisher=Ministry of Health and Family Welfare, Government of India |access-date=24 September 2013 |url-status=dead |archive-url=https://web.archive.org/web/20150221053621/http://cdsco.nic.in/html/drugsbanned.html |archive-date=21 February 2015 }}{{cite web|title=Drug Effects – Methaqualone|url=http://www.saps.gov.za/drugs/meth.htm|publisher=South African Police Service|access-date=24 September 2013|url-status=live|archive-url=https://web.archive.org/web/20030829010929/http://www.saps.gov.za/drugs/meth.htm|archive-date=29 August 2003}}

|1990

|UK, others

|Uveitis.

|1965

|US

|Unspecific experimental toxicity.

|1998

|European Union, Malaysia, US, others

|Fatal arrhythmia, drug interactions.

|1996

|France

|Convulsions.

|1993

|France

|Necrotic hepatitis.

|1987

|France, Germany, European Union

|Polyneuropathy.

|2005–2006

|US

|Voluntarily withdrawn from US market because of risk of Progressive multifocal leukoencephalopathy (PML). Returned to market July 2006.

|2004

|Europe, Australia, New Zealand and Canada{{cite news|last=Cosgrove-Mather|first=Bootie|title=Anti-Depressant Taken Off Market|url=https://www.cbsnews.com/news/anti-depressant-taken-off-market/|access-date=29 September 2013|newspaper=CBS NEWS|date=December 5, 2007|url-status=live|archive-url=https://web.archive.org/web/20131002034206/http://www.cbsnews.com/8301-18563_162-612150.html|archive-date=2 October 2013}}{{cite journal |last1=Babai |first1=S |last2=Auclert |first2=L |last3=Le-Louët |first3=H |title=Safety data and withdrawal of hepatotoxic drugs. |journal=Therapie |date=November 2021 |volume=76 |issue=6 |pages=715–723 |doi=10.1016/j.therap.2018.02.004 |pmid=29609830}}{{cite journal |last1=Lexchin |first1=Joel |title=Drug withdrawals from the Canadian market for safety reasons, 1963–2004 |url=https://www.cmaj.ca/content/172/6/765 |journal=Canadian Medical Association Journal |access-date=29 October 2023 |pages=765–767 |language=en |doi=10.1503/cmaj.045021 |date=15 March 2005|volume=172 |issue=6 |pmid=15767610 |pmc=552890 }}

|Branded version withdrawn by originator in several countries in 2007 for hepatotoxicity. Generic versions available. Still available in US market.

|1974

|UK, US

|Hepatotoxicity, drug intereaction.

|1988

|multiple markets

|CNS Stimulation.

|1984

|Germany

|Hepatic and hematologic toxicity.

|1981–1986

|France, Germany, Spain, UK, US, others

|Hemolytic Anemia, hepatotoxicity, serious hypersensitive reactions.

|1976

|Canada, UK, US (1976)

|Carcinogen.{{cite web|last=DrugBank|title=Oxeladin|url=http://www.drugbank.ca/drugs/DB04822|access-date=24 September 2013|url-status=live|archive-url=https://web.archive.org/web/20130927055002/http://www.drugbank.ca/drugs/DB04822|archive-date=27 September 2013}}

|1984–1985

|UK, US, Germany, France, Canada

|Bone marrow suppression, Stevens–Johnson syndrome.{{cite web|last=DrugBank|title=Oxyphenbutazone|url=http://www.drugbank.ca/drugs/DB03585|access-date=24 September 2013|url-status=live|archive-url=https://web.archive.org/web/20130927055152/http://www.drugbank.ca/drugs/DB03585|archive-date=27 September 2013}}{{cite journal |last1=Biron |first1=P |title= Withdrawal of oxyphenbutazone: what about phenylbutazone? |journal= CMAJ: Canadian Medical Association Journal |date=15 May 1986 |volume=134 |issue=10 |pages= 1119–20 |pmid= 3697857 |pmc= 1491052}}

|1970s

|Australia, France, Germany, UK, US

|Hepatotoxicity.

|2010

|US

|No improvement in clinical benefit; risk for death; veno-occlusive disease.

|1997

|Canada, UK

|Withdrawn from US in 2005 due to hepatotoxicity.{{cite web|last=DrugBank|title=Pemoline|url=http://www.drugbank.ca/drugs/DB01230|access-date=24 September 2013|url-status=live|archive-url=https://web.archive.org/web/20130927055300/http://www.drugbank.ca/drugs/DB01230|archive-date=27 September 2013}}

|1980

|Norway

|Risk of fatal overdose.

|1982

|US

|Withdrawn for inability to produce effective convulsive therapy, and for causing seizures.

|2007

|US

|Risk for heart valve damage.

|1985

|UK, Spain

|Neurologic and hepatic toxicity.

|1975

|Canada

|An ingredient in "A.P.C." tablet; withdrawn because of risk of cancer and kidney disease{{cite web|last=DrugBank|title=Phenacetin|url=http://www.drugbank.ca/drugs/DB03783|access-date=24 September 2013|url-status=live|archive-url=https://web.archive.org/web/20130927055244/http://www.drugbank.ca/drugs/DB03783|archive-date=27 September 2013}} Germany Denmark, UK, US, others Reason: nephropathy.

|1977

|France, Germany US

|Severe lactic acidosis

|1997

|US

|Possible carcinogen.{{cite journal|last1=Wysowski|first1=Diane K.|title=Adverse Drug Event Surveillance and Drug Withdrawals in the United States, 1969–2002: The Importance of Reporting Suspected Reactions|journal=Archives of Internal Medicine|year=2005|volume=165|issue=12|pages=1363–9|doi=10.1001/archinte.165.12.1363|pmid=15983284 |last2=Swartz |first2=L|doi-access=free}}

|1966

|UK

|Hepatotoxicity, drug intereaction.

|1985

|Germany

|Off-label abuse, hematologic toxicity.

|2000

|Canada, US

|Hemorrhagic stroke.{{cite web|url=https://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm172959.htm|title=Safety Alerts for Human Medical Products – Phenylpropanolamine hydrochloride (PPA)|first=Office of the|last=Commissioner|website=Food and Drug Administration|access-date=28 November 2016|url-status=live|archive-url=https://web.archive.org/web/20161023082829/https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm172959.htm|archive-date=23 October 2016}}{{cite web|last=DrugBank|title=Phenylpropanolamine|url=http://www.drugbank.ca/drugs/DB00397|access-date=24 September 2013|url-status=live|archive-url=https://web.archive.org/web/20130927055248/http://www.drugbank.ca/drugs/DB00397|archive-date=27 September 2013}}

|1976

|France

|Neuropsychiatric reaction.

|1990

|France, Germany, Spain

|Liver toxicity.{{rp|223}}

|1988

|Canada, France, Germany, UK, US, others

|Cardiac arrhythmia{{cite web|last=DrugBank|title=Prenylamine|url=http://www.drugbank.ca/drugs/DB04825|access-date=24 September 2013|url-status=dead|archive-url=https://web.archive.org/web/20130927055050/http://www.drugbank.ca/drugs/DB04825|archive-date=27 September 2013}} and death.

|1989

|Germany

|Respiratory reaction.

|1965

|UK

|Animal carcinogenicity.

|1983

|UK

|Allergy.

|1998

|Spain, France, Italy, Portugal, Turkey

|Immunoallergic, thrombocytopenia.

|1979

|France

|Abuse.

|2020

|Worldwide

|Found to spontaneously break down into the carcinogen N-nitrosodimethylamine.

|2001

|US, multiple markets

|Withdrawn in many countries because of risk of fatal bronchospasm.

|1993

|UK, others

|Aplastic anemia.

|1999

|US

|Withdrawn due to risk of intussusception.{{cite web|url=https://www.cdc.gov/mmwr/preview/mmwrhtml/mm4843a5.htm|title=Withdrawal of Rotavirus Vaccine Recommendation|website=www.cdc.gov}}

|2008

|Worldwide

|Risk of severe depression and suicide.

|2004

|Worldwide

|Withdrawn by Merck & Co. Risk of myocardial infarction and stroke.

|2010

|Europe

|Risk of heart attacks and death. This drug continues to be available in the US

|{{When|date=January 2025}}

|France, Norway, others.{{Which|date=January 2025}}

|Risk of overdose

|1998

|European Union

|Arrhythmia and sudden cardiac death{{cite web|last=DrugBank|title=Sertindole|url=http://www.drugbank.ca/drugs/DB06144|access-date=24 September 2013|url-status=live|archive-url=https://web.archive.org/web/20130927055004/http://www.drugbank.ca/drugs/DB06144|archive-date=27 September 2013}}

|2010

|Australia,{{cite web|url=http://sibutramine.com/australia/en-au/ |title=Sibutramine (brand name Reductil) Information – Australia |year=2010 |access-date=2010-10-08 |publisher=Abbott Laboratories |url-status=dead |archive-url=https://web.archive.org/web/20101014014348/http://sibutramine.com/australia/en-au/ |archive-date=2010-10-14 }} Canada,[http://hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2010/meridia_hpc-cps-eng.php Health Canada Endorsed Important Safety Information on MERIDIA (Sibutramine Hydrochloride Monohydrate)] {{webarchive|url=https://web.archive.org/web/20130111132644/http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2010/meridia_hpc-cps-eng.php |date=2013-01-11 }}: Subject: Voluntary withdrawal of Meridia (sibutramine) capsules from the Canadian market. China,{{cite web |url=http://www.sda.gov.cn/WS01/CL0195/55333.html |title=Notification of Termination of Production, Sale, and Usage of Sibutramine Preparations and Their Active Pharmaceutical Ingredient |publisher=sda.gov in People's Republic of China |date=October 30, 2010 |access-date=2011-05-21 |url-status=dead |archive-url=https://web.archive.org/web/20111007065924/http://www.sda.gov.cn/WS01/CL0195/55333.html |archive-date=October 7, 2011 }} the European Union (EU),{{in lang|de}} Sibutramin-Vertrieb in der Europäischen Union ausgesetzt [https://archive.today/20120719155409/http://www.abbott.de/content/e17/e127/e15940/index_de.html]. Abbott Laboratories in Germany. Press Release 2010-01-21. Retrieved 2010-01-27 Hong Kong,{{cite press release |url=http://www.info.gov.hk/gia/general/201011/02/P201011020204.htm |title=De-registration of pharmaceutical products containing sibutramine |publisher=info.gov in Hong Kong |date=November 2, 2010 |access-date=2010-11-08 |url-status=live |archive-url=https://web.archive.org/web/20111021074543/http://www.info.gov.hk/gia/general/201011/02/P201011020204.htm |archive-date=October 21, 2011 }} India,{{cite press release |url=http://pib.nic.in/newsite/erelease.aspx?relid=70841 |title=Banned Medicines |publisher=Ministry of Health and Family Welfare |date=February 10, 2011 |access-date=2011-03-15 |url-status=live |archive-url=https://web.archive.org/web/20120723055422/http://pib.nic.in/newsite/erelease.aspx?relid=70841 |archive-date=July 23, 2012 }} Mexico, New Zealand,{{cite press release|url=http://www.medsafe.govt.nz/hot/media/2010/SibutramineOct2010.asp |title=Withdrawal of Sibutramine (Reductil) in New Zealand |publisher=MedSafe in New Zealand |date=October 11, 2010 |access-date=2012-11-06 |url-status=dead |archive-url=https://web.archive.org/web/20121014130417/http://medsafe.govt.nz/hot/media/2010/SibutramineOct2010.asp |archive-date=October 14, 2012 }} the Philippines,{{cite news|title=FDA warns online sellers of banned slimming pills|url=http://business.inquirer.net/159883/fda-warns-online-sellers-of-banned-slimming-pills|access-date=February 20, 2014|date=January 12, 2014|url-status=live|archive-url=http://archive.wikiwix.com/cache/20140221073844/http://business.inquirer.net/159883/fda-warns-online-sellers-of-banned-slimming-pills|archive-date=February 21, 2014}} Thailand,{{cite press release |url=http://elib.fda.moph.go.th/fulltext2/word/41633/41633.pdf |title=Thai FDA reveals voluntary withdrawal of sibutramine from the Thai market |publisher=Food and Drug Administration of Thailand |date=October 20, 2010 |access-date=2010-12-22 |url-status=dead |archive-url=https://web.archive.org/web/20110511225841/http://elib.fda.moph.go.th/fulltext2/word/41633/41633.pdf |archive-date=May 11, 2011 }} the United Kingdom,{{cite news |url=http://news.bbc.co.uk/1/hi/health/8473555.stm |title=Top obesity drug sibutramine being suspended |access-date=2010-01-22 |work=BBC News |date=2010-01-22 |url-status=live |archive-url=https://web.archive.org/web/20100125005254/http://news.bbc.co.uk/1/hi/health/8473555.stm |archive-date=2010-01-25 }} and the United States{{cite news|last1=Rockoff|first1=Jonathan D.|last2=Dooren|first2=Jennifer Corbett|title=Abbott Pulls Diet Drug Meridia Off US Shelves|url=https://online.wsj.com/article/BT-CO-20101008-710904.html|access-date=8 October 2010|newspaper=The Wall Street Journal|date=October 8, 2010|url-status=live|archive-url=https://web.archive.org/web/20101011004015/http://online.wsj.com/article/BT-CO-20101008-710904.html|archive-date=11 October 2010}}

|Increased risk of heart attack and stroke.

|2010

|Germany

|Hepatotoxicity.

|1993

|Japan

|Drug interaction and deaths.H. Gurdon: [http://www.bmj.com/cgi/content/full/309/6955/627 Japan bans shingles drug after deaths] {{webarchive|url=https://web.archive.org/web/20030626184906/http://bmj.com/cgi/content/full/309/6955/627 |date=2003-06-26 }} BMJ 1994;309:627

|2001

|US

|QT prolongation and phototoxicity.

|1988

|Germany

|Dermatologic, hematologic and hepatic reactions.

|1988

|Germany

|Unknown.

|1986

|UK

|Dermatologic and hematologic reactions.

|1985

|Germany, France, Spain

|Hepatotoxicity.

|1986–1987

|UK, Spain, US

|Kidney damage.

|2007

|US

|Risk for heart attack, stroke, and unstable angina. Was available through a restricted access program until April 2008; returned to market in 2019.

|1992

|Germany, UK, US, others

|Low blood sugar; hemolytic anemia; kidney, liver dysfunction; allergic reactions

|1992

|US

|Allergic reactions and cases of hemolytic anemia, leading to three patient deaths.[https://www.fda.gov/bbs/topics/NEWS/NEW00279.html]

|1999

|Sweden, Norway

|Diversion, abuse, and a relatively high rate of overdose deaths in comparison to other drugs of its group. This drug continues to be available in most of the world including the US, but under strict controls.

|1997–1998

|France, South Africa, Oman, others, US

|Prolonged QT interval; ventricular tachycardia

|1991

|Germany, UK, Spain, others

|Prolonged QT interval, ventricular tachycardia and arrhythmia.

|2013

|European Union

|Serious cutaneous reactions.{{cite web|last=Paar|first=W.D|title=Ruhen der Zulassung Tetrazepam haltiger Arzneimittel in der EU (German)|url=http://www.akdae.de/Arzneimittelsicherheit/RHB/20130624.pdf|publisher=Sanofi-Aventis Deutschland GmbH|access-date=25 September 2013|author2=Müller-Jakic|url-status=dead|archive-url=https://web.archive.org/web/20130927164219/http://www.akdae.de/Arzneimittelsicherheit/RHB/20130624.pdf|archive-date=27 September 2013}}

|1961

|Germany

|Withdrawn because of risk of teratogenicity;{{cite news|last=Luippold|first=Gerd|title=Renaissance des Contergan-Wirkstoffs|url=http://www.pharmazeutische-zeitung.de/index.php?id=586|access-date=25 September 2013|newspaper=Pharmazeutische Zeitung (German)|year=2006|url-status=live|archive-url=https://web.archive.org/web/20130927201808/http://www.pharmazeutische-zeitung.de/index.php?id=586|archive-date=27 September 2013}} returned to market for use in leprosy and multiple myeloma under FDA orphan drug rules

|1963

|Canada, UK, US

|Neutropenia{{cite web|last=Drugbank|title=Thenalidine|url=http://www.drugbank.ca/drugs/DB04826|access-date=24 September 2013|url-status=dead|archive-url=https://web.archive.org/web/20130927055254/http://www.drugbank.ca/drugs/DB04826|archive-date=27 September 2013}}

|1993

|Germany

|Kidney injury.

|2005

|Germany, UK

|Withdrawn worldwide due to severe cardiac arrhythmias{{cite journal|title=Outcome of patients after market withdrawal of thioridazine: A retrospective analysis in a nationwide cohort|journal=Pharmacoepidemiology and Drug Safety|volume=21|issue=11|date=November 2012|pmid=22941581|doi=10.1002/pds.3346|pages=1227–1231|author1=Purhonen, M |author2=Koponen, H |author3=Tiihonen, J |author4=Tanskanen, A |s2cid=19560432}}{{cite web|title=SHARED CARE PROTOCOL Thioridazine|work=NHS Lothian Joint Formulary|date=March 2012|url=http://www.ljf.scot.nhs.uk/SharedCareofMedicines/Shared%20Care%20Agreements/SCA/SCA%20Thioridazine%20v1%200%20Final.pdf|url-status=dead|archive-url=https://web.archive.org/web/20150518080549/http://www.ljf.scot.nhs.uk/SharedCareofMedicines/Shared%20Care%20Agreements/SCA/SCA%20Thioridazine%20v1%200%20Final.pdf|archive-date=2015-05-18}} Continues to be available in Russia.

|1980

|Germany, France, UK, US others

|Liver toxicity and death.

|1998

|European Union, Canada, Australia

|Hepatotoxicity

|1996

|Argentina, Canada, Italy, others

|Severe hepatotoxicity

|1971

|Australia

|Hepatotoxicity.

|1991

|France, Netherlands, Finland, Argentina, UK others

|Psychiatric adverse drug reactions, amnesia.{{cite web|last=DrugBank|title=Triazolam|url=http://www.drugbank.ca/drugs/DB00897|access-date=24 September 2013|url-status=dead|archive-url=https://web.archive.org/web/20130927041923/http://www.drugbank.ca/drugs/DB00897|archive-date=27 September 2013}}

|1962

|France, US

|Cataracts, alopecia, ichthyosis.

|2000

|US, Germany

|Hepatotoxicity

|1999–2001

|European Union, US

|Withdrawn because of risk of liver failure

|2004

|US

|Risk of heart attack and stroke.

|1987

|Germany

|Hematologic toxicity.

|1965

|France

|Hepatotoxicity.

|2006

|Germany

|Hepatotoxicity

|1983

|Worldwide

|Risk of Guillain–Barré syndrome, hypersensitivity reaction, hepatotoxicity{{cite journal | pmc=1028185 | year=1985 | last1=Fagius | first1=J. | last2=Osterman | first2=P. O. | last3=Sidén | first3=A. | last4=Wiholm | first4=B. E. | title=Guillain-Barré syndrome following zimeldine treatment | journal=Journal of Neurology, Neurosurgery, and Psychiatry | volume=48 | issue=1 | pages=65–69 | doi=10.1136/jnnp.48.1.65 | pmid=3156214 }}[https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46504589&viewopt=PubChem Pubchem record] {{webarchive|url=https://web.archive.org/web/20150610232146/http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46504589&viewopt=PubChem |date=2015-06-10 }} says "withdrawn in 1983" banned worldwide.{{cite web|last=DrugBank|title=Zimelidine|url=http://www.drugbank.ca/drugs/DB04832|access-date=24 September 2013|url-status=live|archive-url=https://web.archive.org/web/20130927055154/http://www.drugbank.ca/drugs/DB04832|archive-date=27 September 2013}}

|1983

|UK, Germany, Spain, US

|Anaphylactic reactions and non-fatal allergic reactions, kidney failure